Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elizabeth Lazaridou is active.

Publication


Featured researches published by Elizabeth Lazaridou.


Journal Der Deutschen Dermatologischen Gesellschaft | 2011

The potential role of microorganisms in the development of rosacea.

Elizabeth Lazaridou; Christina Giannopoulou; Christina Fotiadou; Eustratios Vakirlis; Anastasia Trigoni; D. Ioannides

Rosacea is a chronic cutaneous disorder characterized by centrofacial persisting erythema, telangiectases, papules, pustules, edema, phymas and ocular involvement. Despite being one of the most common skin disorders, its pathogenesis remains unclear and controversial. Although the disease triggering factors are well recognized, the underlying causes of rosacea have not yet been identified. Several different postulates about its pathogenesis can be found in the medical literature. Abnormalities of the pilosebaceous unit, as well as genetic, vascular, inflammatory, environmental and microbial factors have been described. The microorganisms that have been associated include Helicobacter pylori, Demodex folliculorum, Staphylococcus epidermidis, and Chlamydia pneumonia; all the studies have been inconclusive. We review currently available scientific data on the potential pathogenetic role of microorganisms in the development of rosacea.


Journal of The European Academy of Dermatology and Venereology | 2010

Clinical and laboratory study of rosacea in northern Greece

Elizabeth Lazaridou; Z. Apalla; S Sotiraki; Nikolas G Ziakas; C Fotiadou; D. Ioannides

Background  Numerous factors have been implicated in the pathogenesis of rosacea, which remains obscure.


The Clinical Journal of Pain | 2013

Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial.

Zoe Apalla; Elena Sotiriou; Aimilios Lallas; Elizabeth Lazaridou; Demetrios Ioannides

Objectives:Cumulative evidence support a beneficial effect of botulinum toxin A (BTX-A) in postherpetic neuralgia (PHN). We aimed to assess efficacy, safety, and tolerability of BTX-A in the management of PHN, performing a randomized, double-blind, single-dose, placebo-controlled trial. Methods:Thirty adults with PHN were randomized either to BTX-A or placebo. Severity of pain was evaluated by patients using a visual analogue scale (VAS) and quality of sleep was assessed using a 5-item questionnaire. Primary outcome was reduction in VAS score, with a greater than 50% reduction being considered clinically significant. Secondary outcomes were reduction in sleep score and maintenance of VAS score after treatment, with over 50% maintenance considered clinically meaningful. Results:Thirteen patients from the experimental arm achieved an at least 50% reduction in VAS score, compared with none of the placebo patients (NNT=1.2, 95% CI, 2-1; ARR=0.87, 95% CI, 055-096; P<0.001). BTX-A patients showed significant reduction in VAS pain scores between baseline and week 2, which persisted for a median period of 16 weeks. BTX-A patients showed significant reduction in sleep scores between baseline and week 2, which remained unchanged until 16th week (P<0.001). Treatment was well tolerated. Discussion:Data confirm that BTX-A is effective and well tolerated in the treatment of PHN.


Journal of The European Academy of Dermatology and Venereology | 2013

Dermoscopy of early stage mycosis fungoides

A. Lallas; Z. Apalla; Ioanna Lefaki; Thrassivoulos Tzellos; Athanasios Karatolias; Eleni Sotiriou; Elizabeth Lazaridou; D. Ioannides; Iris Zalaudek; Giuseppe Argenziano

Background  Early stage mycosis fungoides (MF) is difficult to be clinically differentiated from chronic dermatitis (CD) in a high proportion of patients. Dermoscopy is a rapid, cheep, non‐invasive and widely used method for the evaluation of skin tumours and, recently, of inflammatory skin diseases, as well.


Journal of Dermatological Case Reports | 2012

Spontaneous abortion during ustekinumab therapy

Christina Fotiadou; Elizabeth Lazaridou; Eleni Sotiriou; Demetrios Ioannides

BACKGROUND Psoriasis affects a considerable proportion of women in their reproductive years. Limited published data exist about the possible negative impact of the disease itself in the prognosis of pregnancy. On this background, the emergence of newer biologic agents for psoriasis treatment - such as ustekinumab - raises safety issues concerning the exposure to the drug during pregnancy. To our knowledge this is the first report in the literature describing a pregnancy outcome under ustekinumab treatment. OBSERVATION We report a 35-year-old female psoriasis patient who was under treatment with ustekinumab for a year when she inadvertedly became pregnant. The drug was discontinued immediately and the patient did not opt for termination. During the 12th week of gestation she experienced a spontaneous abortion. CONCLUSION Although the patients profile fulfilled 2 general risk factors for spontaneous abortion - she was a smoker and this was her third pregnancy - one could not underestimate the possible role of the drug and of psoriasis per se in this adverse pregnancy outcome. Pregnancy registries and large prospective studies are needed in order to determine whether poorer pregnancies outcomes in psoriatic women are due to the disease itself, associated comorbidities or side-effects of new therapies such as ustekinumab.


Journal of The European Academy of Dermatology and Venereology | 2011

Safety of anti‐tumour necrosis factor‐α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature

Christina Fotiadou; Elizabeth Lazaridou; D. Ioannides

Background  Issues concerning the potential risks of reactivating chronic hepatitis B virus arise when the use of anti‐Tumour Necrosis Factor‐α (TNFα) agents is imperative in patients with concurrent psoriasis and hepatitis B virus infection.


British Journal of Dermatology | 2013

Dermoscopy of discoid lupus erythematosus

Aimilios Lallas; Z. Apalla; Ioanna Lefaki; Eleni Sotiriou; Elizabeth Lazaridou; D. Ioannides; Danica Tiodorovic-Zivkovic; Theodoros Sidiropoulos; D. Konstantinou; V. Di Lernia; Giuseppe Argenziano; Iris Zalaudek

Summary Background  Dermoscopy is useful in evaluating skin tumours, but its applicability also extends into the field of inflammatory skin disorders. Discoid lupus erythematosus (DLE) represents the most common subtype of cutaneous lupus erythematosus. While dermoscopy and videodermoscopy have been shown to aid the differentiation of scalp DLE from other causes of scarring alopecia, limited data exist concerning dermoscopic criteria of DLE in other locations, such as the face, trunk and extremities.


Adolescent Health, Medicine and Therapeutics | 2014

Management of psoriasis in adolescence

Christina Fotiadou; Elizabeth Lazaridou; Demetrios Ioannides

Psoriasis is a chronic inflammatory cutaneous disorder affecting 2%–4% of the world’s population. The prevalence of the disease in childhood and adolescence ranges between 0.5% and 2%. The management of psoriasis in adolescence is an intriguing and complicated task. Given the paucity of officially approved therapies, the very limited evidence-based data from randomized controlled trials, and the absence of standardized guidelines, physicians must rely on published experience from case reports both from the field of dermatology as well as from the application of these drugs for other pediatric conditions coming from the disciplines of rheumatology, gastroenterology, and oncology. Psoriatic adolescents deal with a potentially disfiguring and lifelong disease that could permanently impair their psychological development. It must be clarified to them that psoriasis does not have a permanent cure, and therefore the main goal of treatments is to establish disease control and prolonged periods between flares. The majority of adolescents suffer from mild psoriasis, and thus they are treated basically with topical treatment modalities. Phototherapy is reserved for adolescents with mild-to-moderate plaque disease and/or guttate psoriasis when routine visits to specialized centers do not create practical problems. Systemic agents and biologics are administered to patients with moderate-to-severe plaque psoriasis, pustular psoriasis, or erythrodermic psoriasis.


Journal of The European Academy of Dermatology and Venereology | 2011

Clinical and laboratory study of ocular rosacea in northern Greece.

Elizabeth Lazaridou; Christina Fotiadou; Nikolas G Ziakas; C. Giannopoulou; Z. Apalla; D. Ioannides

Background  The prevalence of ophthalmic involvement in rosacea is probably higher than previously presumed and varies considerably among several studies.


Dermatology practical & conceptual | 2017

Epidemiological trends in skin cancer.

Zoe Apalla; Aimilios Lallas; Elena Sotiriou; Elizabeth Lazaridou; Demetrios Ioannides

Skin cancer, including melanoma and non-melanoma skin cancer (NMSC), represents the most common type of malignancy in the white population. The incidence rate of melanoma is increasing worldwide, while the associated mortality remains stable, or is slightly decreasing. On the other hand, the incidence for NMSC varies widely, with the highest rates reported in Australia. In the current review, we highlight recent global trends in epidemiology of skin cancer. We discuss controversial issues raised in current epidemiological data, we analyze the most important risk factors associated with the development of melanoma and NMSC and the impact of skin cancer on health care services. Furthermore, we underline the pressing need for improved registration policies, especially for NMSC, and lastly, we refer to the ongoing primary and secondary prevention strategies and their outcomes so far.

Collaboration


Dive into the Elizabeth Lazaridou's collaboration.

Top Co-Authors

Avatar

D. Ioannides

Aristotle University of Thessaloniki

View shared research outputs
Top Co-Authors

Avatar

Z. Apalla

Aristotle University of Thessaloniki

View shared research outputs
Top Co-Authors

Avatar

Elena Sotiriou

Aristotle University of Thessaloniki

View shared research outputs
Top Co-Authors

Avatar

Efstratios Vakirlis

Aristotle University of Thessaloniki

View shared research outputs
Top Co-Authors

Avatar

A. Lallas

Aristotle University of Thessaloniki

View shared research outputs
Top Co-Authors

Avatar

Zoe Apalla

Aristotle University of Thessaloniki

View shared research outputs
Top Co-Authors

Avatar

Demetrios Ioannides

Aristotle University of Thessaloniki

View shared research outputs
Top Co-Authors

Avatar

Eleni Sotiriou

Aristotle University of Thessaloniki

View shared research outputs
Top Co-Authors

Avatar

Aimilios Lallas

Aristotle University of Thessaloniki

View shared research outputs
Top Co-Authors

Avatar

Aikaterini Patsatsi

Aristotle University of Thessaloniki

View shared research outputs
Researchain Logo
Decentralizing Knowledge